In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market at $25 billion (₹2.12 lakh crore) and the global market approaching $2.6 trillion (₹221 lakh crore). But there is a second, more dangerous number that rarely appears on a profit and loss statement: $500 billion (₹42.5 lakh crore).
According to 2025–2026 analyses from Frontiers in Pharmacology and OECD health working papers, the global economic burden of medication non-adherence—the failure to take prescriptions as directed—exceeds $500 billion (₹42.5 lakh crore) annually. This is the "Global Adherence Leak": money wasted not on buying drugs, but on the catastrophic medical complications that occur when patients skip them.
For India, a nation where Non-Communicable Diseases (NCDs) cause 60% of all deaths, this leak is more than a financial drain—it is a public health crisis waiting for an entrepreneurial solution.
Free Membership Required
You must be a Free member to access this content.
